IL11 and lung adenocarcinoma: Introduction of two additional point mutations ablated binding to the gp130 coreceptor at two putative IL‐11 binding sites, resulting in an antagonist that disrupts the active signaling complex and decreases lung adenocarcinoma progression in a mouse tumor model.